SSTR5

Across TCGA pan-cancer cohorts, SSTR5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SSTR5 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher SSTR5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SSTR5 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

BRCA, GBM, and PRAD are the cancer types where SSTR5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	II,III,IV	0.735	0.958	<.001	10	view →
GBM	DFS	Median	All	0.043	0.243	.003	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.680	.016	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SSTR5–BRCA (OS)

Open the BRCA breakdown →